News

CLINUVEL
Posted by CLINUVEL
March 18, 2016

Form 604

18 March 2016 Enclosed is a Notice of Change of Interests of Substantial...

Read More
CLINUVEL
Posted by CLINUVEL
March 15, 2016

Form 604 - March 15, 2016

15 March 2016 Enclosed is a notice of a change of interest...

Read More
CLINUVEL
Posted by CLINUVEL
March 13, 2016

CLINUVEL accredits first European EPP expert centres

 13 March 2016 CLINUVEL Pharmaceuticals Limited (ASX: CUV; XETRA-DAX: UR9; ADR: CLVLY)...

Read More
CLINUVEL
Posted by CLINUVEL
March 13, 2016

CLINUVEL placement of A$8.3 million completed successfully

13 March 2016 ** Not for release or distribution in the United...

Read More
CLINUVEL
Posted by CLINUVEL
March 11, 2016

Request for Trading Halt

11 March 2016 Pursuant to Listing Rule 17.1, Clinuvel Pharmaceuticals Ltd (CUV)...

Read More
CLINUVEL
Posted by CLINUVEL
February 19, 2016

Appendix 4D and Half Year Report

19 February 2016 Your Directors present their report on the company and...

Read More
CLINUVEL
Posted by CLINUVEL
February 13, 2016

CLINUVEL brief on European commercialisation

19 February 2016 CLINUVEL Pharmaceuticals Limited (ASX: CUV; XETRA-DAX: UR9; ADR: CLVLY)...

Read More
CLINUVEL
Posted by CLINUVEL
February 10, 2016

SCENESSE® receives US FDA orphan designation for cutaneous porphyrias

10 February 2016 Clinuvel Pharmaceuticals Limited (ASX: CUV; XETRA-DAX: UR9; ADR: CLVLY)...

Read More
CLINUVEL
Posted by CLINUVEL
February 7, 2016

Presentation to international porphyria patient group

8 February 2016 Clinuvel Pharmaceuticals Ltd (ASX: CUV; XETRA‐DAX: UR9; ADR: CLVLY)...

Read More
CLINUVEL
Posted by CLINUVEL
January 28, 2016

Appendix 4C - Q2 FY16

28 January 2016 Enclosed is a copy of the Quarterly report for...

Read More
We use cookies to give you the best experience.